SCHEMBL4897167

SCHEMBL4897167

COc1cc(/C=C/C(=O)O)cc(Br)c1OCc1ccc2ccccc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.61
ABCG2 Q9UNQ0 4/20 0.60
KDM4E B2RXH2 2/20 0.51
GAA P10253 1/20 0.51
ABCB1 P08183 1/20 0.51
ALDH1A1 P00352 3/20 0.50
HTR1A P08908 2/20 0.50
HPGD P15428 1/20 0.50
HTR2C P28335 1/20 0.50
HSD17B10 Q99714 1/20 0.50
TNFRSF1A P19438 4/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
MAPT P10636 3/20 0.48
LMNA P02545 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 2/20 0.48
CYP2C19 P33261 2/20 0.48
HSP90AA1 P07900 1/20 0.48
XBP1 P17861 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4897176 1.00 APP (0.61) APPABCG2KDM4EGAAABCB1
SCHEMBL4900593 0.90 KDM4E (0.50) APPABCG2KDM4EALDH1A1LMNA
SCHEMBL4900599 0.90 KDM4E (0.50) APPABCG2KDM4EALDH1A1LMNA
SCHEMBL4897770 0.85 APP (0.61) APPKDM4EGAAALDH1A1HTR1A
SCHEMBL4897767 0.85 APP (0.61) APPKDM4EGAAALDH1A1HTR1A
SCHEMBL7512551 0.81 KDM4E (0.64) APPKDM4EALDH1A1HTR1AHPGD
SCHEMBL7512554 0.81 KDM4E (0.64) APPKDM4EALDH1A1HTR1AHPGD
SCHEMBL27743558 0.80 TNFRSF1A (0.60) APPKDM4EGAAALDH1A1HTR1A
SCHEMBL22555959 0.79 KDM4E (0.62) APPKDM4EALDH1A1HTR1AHPGD
SCHEMBL17211760 0.77 KDM4E (0.63) APPKDM4EGAAALDH1A1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080027096-A1 Novel Pharmaceutical Compositions KARO BIO AB (SE) 2008-01-31 US disclosed
EP-1729756-A2 NOVEL PHARMACEUTICAL COMPOSITIONS KARO BIO AB (SE) 2006-12-13 EP disclosed
WO-2005094810-A2 NOVEL PHARMACEUTICAL COMPOSITIONS KARO BIO AB (SE) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027096-A1 Novel Pharmaceutical Compositions AR, NR5A1, CYP17A1 APP 3171/4885ABCG2 547/4885KDM4E 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.